Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AS1411 in Metastatic Renal Cell Carcinoma
NCT00740441Phase 2Unknown
- Sponsor
- Antisoma
- Start
- Aug 2008
- Primary completion
- Sep 2009
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of as1411 in metastatic renal cell carcinoma (mRCC), sponsored by Antisoma. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
as1411
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00740441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00740441.